Summary 42 43 Long-lasting forms of postsynaptic plasticity commonly involve protein synthesis-dependent 44 structural changes of dendritic spines. However, the relationship between protein synthesis and 45 presynaptic structural plasticity remains unclear. Here, we investigated structural changes in 46 cannabinoid-receptor 1 (CB1)-mediated long-term depression of inhibitory transmission (iLTD), a 47 form of presynaptic plasticity that requires protein synthesis and involves a long-lasting 48 reduction in GABA release. We found that CB1-iLTD in acute rat hippocampal slices was 49 associated with protein synthesis-dependent presynaptic structural changes. Using proteomics, 50
Synaptic plasticity, the ability of synapses to change their strength in response to activity or 72 experience, underlies information storage in the brain. While presynaptic forms of plasticity, i.e. 73 long-term synaptic strengthening (long-term potentiation or LTP) and weakening (long-term 74 depression or LTD) due to long-lasting increase and decrease in neurotransmitter release, 75 respectively, are widely expressed in the brain, their mechanism remains poorly understood 76 Heifets et al., 2008) , but also allows us to shortcut the 135 synthesis and release of eCBs, thereby excluding potential effects of pharmacological inhibitors 136 (see below) on these processes. 137
Using CB1 immunolabeling, which accurately approximates bouton volume (Dudok et al., 2015) , 138
we found that CB1-iLTD led to a significant decrease of CB1 bouton volume following WIN 139 treatment ( Figure 1C) . This structural change was long-lasting as it persisted for 60 minutes after 140 WIN treatment (Figure 1C) , and it was blocked by concurrent bath application with cycloheximide 141 (80 µM), demonstrating a requirement for protein synthesis (Figure 1C) . The effect was specific 142 because the volume of parvalbumin (PV + ) boutons in the CA1 pyramidal layer, which do not 143 express CB1 receptors (Glickfeld & Scanziani, 2006 ) (Supp. Figure 1A) , was not altered by WIN 144 application (Supp. Figure 1B,C) , as assessed by PV immunolabeling (Younts et al., 2016) . As a 145 complementary approach independent of CB1 labeling, we used Bassoon immunolabeling to 146 assess the size of the presynaptic active zone. Similar to the total bouton volume, Bassoon size 147 within CB1 + boutons was also significantly decreased following WIN application (Figure 1D) . 148
These results strongly suggest that CB1-iLTD is associated with a protein synthesis-dependent 149 shrinkage of CB1 + boutons, which may contribute to the long-lasting reduction in neurotransmitter 150 release observed in this form of plasticity. Along with our previous study (Younts et al., 2016) , our 151 findings indicate that protein synthesis is required for both structural and functional presynaptic 152 changes involved in CB1-iLTD. 153 CB1 activation alters the abundance of proteins linked to protein synthesis, synaptic 154
structure/function and energy metabolism 155
To glean insights into the mechanism(s) underlying structural and functional CB1-iLTD, we sought 156 to identify proteins synthesized upon CB1 activation. We previously showed CB1-dependent 157 increases in protein synthesis were evident after brief CB1 activation in cultured hippocampal 158 neurons (Younts et al., 2016) . To identify and quantitate changes in the neuronal proteome, we 159 Figure 2A, B) . Samples were combined and simultaneously analyzed by tandem MS/MS 165 to identify and quantify changes induced by CB1 receptor activation. To strengthen the robustness 166 of findings, we performed a replicate "reverse" experiment where 'heavy' neurons were treated 167 with WIN and observed a high degree of correlation between replicates (Supp. Figure 2C) . 168
We found significant changes across the protein landscape. Setting a threshold cutoff at 0.5 log2-169 fold change, we found that 33 proteins were upregulated and 27 proteins were downregulated by 170 CB1 activation. Examples of these proteins grouped by their suggested function are shown in 171 Figure 2D) . Similarly, analyses using SynGO (Koopmans et al., 193 2019) , an expert-curated tool to identify GO terms associated with synaptic function, linked our 194 results to regulation of synaptic protein synthesis (Supp. Figure 2E ). Together, these results 195 suggest that both protein synthesis and coincident degradation of structural and presynaptic 196 proteins occur downstream of CB1 activation, and could therefore be implicated in CB1-iLTD. 197
CB1-iLTD involves actin remodeling via Rac1 and Arp2/3 198
CB1 directly interacts with actin branching modulators WAVE1 and Arp2/3 (Njoo et al., 2015) , and 199 these proteins are downregulated in hippocampal neurons following CB1 activation (Figure 2A) , 200 therefore regulation of the abundance of these proteins may represent a mechanism underlying 201 structural and functional presynaptic changes involved in CB1-iLTD. For example, CB1 activation 202 could reduce the presynaptic terminal volume by favoring actin depolymerization. To test this 203 possibility, we first examined whether actin cytoskeletal dynamics were required for CB1-iLTD 204 induced structural plasticity (Figure 1) . Using the same high-resolution microscopy and 3D 205 reconstruction as Figure 1 , we activated CB1 in the presence of jasplakinolide (JSK, 250 nM), a 206 reagent that promotes actin-stabilization (Holzinger, 2009 ). We found that JSK application 207 blocked the WIN-induced decrease in presynaptic bouton volume ( Figure 3A) . These results 208 indicate that actin dynamics likely underlie the structural changes following CB1 activation. To test 209 the functional requirement for actin remodeling in CB1-iLTD, we monitored inhibitory synaptic 210 transmission in the CA1 area by recording extracellular field inhibitory postsynaptic potentials 211 (fIPSP) (see Figure 1) , which allows non-invasive, stable long-term assessment of inhibitory 212 synaptic transmission, and induced CB1-iLTD by bath applying the CB1 agonist WIN 55, 212-2 213 (25 min, 5 µM) (Heifets et al., 2008; Younts et al., 2016) . Similar to the effects on structural 214 plasticity, bath application of JSK impaired CB1-iLTD ( Figure 3B) , whereas JSK application alone 215 had no effect on basal synaptic transmission (Supp. Figure 4A) . These results strongly suggest 216 that actin remodeling is critical for structural and functional CB1-iLTD. 217
The Rac1 GTPase is one of the principal regulators of actin polymerization via WAVE1 and Arp2/3 218 activity (Derivery & Gautreau, 2010; Stradal & Scita, 2006) . To test the role of these proteins, we 219 inhibited Rac1 activity using NSC 23766 (NSC), an inhibitor of Rac1-GEF interaction (Gao et al., Figure 4B ), suggesting Rac1 activity regulates GABA release. To directly test the role of Arp2/3 224 in CB1-iLTD we utilized CK-666 (100 µM), a compound that inhibits Arp2/3-mediated actin 225 assembly by stabilizing the inactive conformation of Arp (see Figure 3G ) (Basu et al., 2016; 226 Hetrick et al., 2013) . CK-666 bath application enhanced CB1-iLTD ( Figure 3E ) suggesting that 227
Arp2/3 participates in CB1-iLTD. Unlike NSC, CK-666 had no effect on basal inhibitory 228 transmission (Supp. Figure 4C) , presumably because the inhibitor stabilizes the inactive 229 (unbound) Arp2/3, but does not affect the Arp2/3 bound to actin filaments. Arpc2 protein (Arp2/3 230 complex subunit 2), an essential component of the Arp2/3 complex, was degraded upon CB1 231 activation in hippocampal neuron cultures (Figure 3F ), suggesting that during normal CB1-iLTD, 232 CB1 activation-mediated Rac1 inhibition leads to removal of Arp2/3 from actin branches, and the 233 subsequent degradation of Arp2/3 ( Figure 3G) . The enhancement of CB1-iLTD by CK-666 234 application probably occurs because the unbound Arp2/3 that is not degraded following CB1 235 activation becomes inhibited and cannot maintain actin branches, thereby resulting in further 236 depolymerization. Together, our findings suggest that Rac1 signaling and loss of Arp2/3 likely 237 underlie the actin remodeling, which is likely required for functional and structural CB1-iLTD 238 ( Figure 3G) . 239
CB1-iLTD requires ubiquitination, but not degradation by the proteasome 240
The simplest interpretation of our findings is that CB1-induced degradation of Arp2/3 and WAVE1 241 led to decreased actin polymerization and reduced presynaptic bouton size (see Figure 2 ). To 242 test the role of protein degradation in this process, we first confirmed that presynaptic proteins 243
identified in the SILAC screen, Munc18-1, Synapsin-1, and α-Synuclein, were significantly 244 reduced by WIN (25 min, 5 µM) in hippocampal cultures (Figure 4A ), suggesting rapid protein 245 degradation upon CB1 activation. To assess whether presynaptic proteins are degraded locally in 246 acute hippocampal slices, we prevented anterograde and retrograde axonal transport by 247 incubating slices in nocodazole (1 hr, 20 µM), an agent that depolymerizes axonal microtubules 248 (Barnes et al., 2010; Younts et al., 2016) . We found that CB1 activation with WIN reduced 249
Synapsin-1 puncta intensity in CB1 + boutons despite blockade of axonal transport (Figure 4B) , 250
as measured by immunostaining and quantitative Airyscan microscopy, consistent with local 251 degradation. These results suggest that CB1 activation elicits rapid degradation of presynaptic 252 proteins in culture and in acute slices. 253
Next, we assessed the overall contribution of the ubiquitin/proteasome system (UPS) to CB1-254 iLTD. First, to dynamically assess the UPS pathway, we measured K48-linked ubiquitinated 255 proteins, the canonical form of ubiquitin linkage (Dantuma & Bott, 2014) , following induction of 256 CB1-iLTD in acute rat hippocampal slices in presence or absence of the specific proteasome 257 inhibitor, MG-132. We found that both net flux, i.e. the amount of ubiquitinated proteins degraded 258 by the proteasome, and the rate of degradation, measured by the ratio between blocked and basal 259 conditions, were significantly increased. These results suggest both a larger pool of protein to 260 degrade as well as a faster turnover rate ( Figure 5A) . However, to our surprise, CB1-iLTD was 261 Figure 5B) . Therefore, while UPS activity is 265 increased downstream of CB1 activation, proteasomal degradation is not necessary for CB1-iLTD. 266
Ubiquitination marks not only targets proteins for degradation, but can also affect their localization 267 and function (Hamilton & Zito, 2013) . We analyzed ubiquitination sites on a subset of proteins that 268 were decreased by CB1 activation and found that most ubiquitination sites (~60%) were located 269 in protein-protein or protein-membrane interaction domains (Supp. Figure 5C ) (Akimov et al., 270 2018), indicating that ubiquitination of these proteins could impact their function. We hypothesized 271 that perhaps protein ubiquitination itself, independent of degradation, may play a role in CB1-iLTD. 272
Using two structurally and mechanistically distinct E1 Ubiquitin ligase inhibitors, ziram and PYR-273 41 (Rinetti & Schweizer, 2010), we directly tested whether ubiquitination was required for CB1-274 iLTD, and found that bath application of ziram or PYR-41 blocked CB1-iLTD ( Figure 5C ) but had 275 no significant effect on basal transmission (Supp. Figure 5D ). Moreover, inhibition of 276 ubiquitination also blocked the CB1-mediated decrease in CB1 + bouton volume ( Figure 5D ). 277
These data strongly suggest that, while protein degradation follows CB1 activation, only protein 278 ubiquitination is required for structural and functional CB1-iLTD. We discovered that CB1-iLTD involves structural changes of the presynaptic bouton that require 284 protein synthesis. We identified the proteins that are synthesized and degraded following CB1 285 activation. Increased proteins are implicated in protein synthesis, processing and degradation, 286
whereas decreased proteins are implicated in presynaptic structure, including Arp2/3, and 287 function. CB1-iLTD involved actin remodeling, Rac1 and Arp2/3 signaling. Unexpectedly, we 288 found that protein ubiquitination, but not proteasomal degradation, is responsible for structural 289 and functional CB1-iLTD. Together, these findings point to a mechanism involving coordinated 290 engagement of multiple cellular processes by which CB1 + presynapses can control their strength 291 in response to CB1 activation. We have recently reported that protein synthesis is required for CB1-iLTD (Younts et al., 2016) . also be a novel mechanism by which local translation is regulated (Bigler et al., 2017) .
353 Surprisingly, we also noted synthesis of proteins involved in protein ubiquitination and protein 354 degradation, which may at least partially explain the mechanism of presynaptic plasticity. 355
356
Our results have not allowed us to identify a particular protein that is being synthesized to mediate 357 CB1-iLTD, but rather are suggestive of a holistic mechanism wherein CB1 activation impacts 358 multiple cellular processes in concert to alter neurotransmitter release in the long-term. Although 359 such a mechanism requires greater coordination, it would also reduce energy expenditure over 360 time, i.e. if a presynaptic terminal will not be releasing neurotransmitter for an extended period of 361 time (hours to days) it makes sense to degrade and recycle the release machinery, to reduce 362 energy production, and to shrink the terminal to make space for new growth. Protein synthesis is 363 likely necessary for the coordination and engagement of these structural, metabolic, and 364 degradative processes. We measured changes in the protein landscape that occur fairly rapidly 365 after CB1-iLTD induction (25 min) given that CB1-iLTD was dependent on protein synthesis during 366 this time window (Younts et al., 2016) . It is likely that additional 'plasticity-related' proteins are 367 synthesized or degraded in the hours that follow iLTD induction. 368 369 Protein degradation and presynaptic function 370 371 Proteomic analysis revealed a population of downregulated proteins involved in presynaptic 372 function and structure, as well as energy metabolism (Figures 1 and 4A) . In contrast, 373 components of the protein degradation pathway, including proteasomal subunits, E2 ubiquitin 374 ligases, and degradative enzymes, were upregulated perhaps reflecting on-demand synthesis 375 which could regulate fast, local presynaptic protein degradation. The tight coupling of translation 376 and degradation in the context of synaptic plasticity was described previously (Klein et al., 2015) , 377
and is presumed to occur widely in the brain as a means of maintaining proteostasis over the 378 However, our data strongly support the idea that protein degradation by the UPS is not directly 386 required for CB1-iLTD, but does occur quickly after CB1 activation, as indicated by rapid loss of 387 presynaptic proteins measured with both SILAC and western blot, presumably as a consequence 388 of enhanced UPS activity (Figure 4) . 389
390
We demonstrated that ubiquitination is required for CB1-iLTD, likely by controlling the trafficking, 391
interactions, or the activity of its substrates, upstream of degradation (Hamilton & Zito, 2013) . A 392 previous study showed that inhibition of protein ubiquitination and degradation increased 393 miniature EPSCs/IPSCs in cultured neurons, suggesting an important role for these processes in 394 maintaining normal neurotransmitter release (Rinetti & Schweizer, 2010) . However, in our hands, 395 proteasomal inhibitor MG-132 had no significant effects on basal synaptic transmission and 396 neither did E1 ubiquitin ligase inhibitors, ziram and PYR-41. To our knowledge, our study is the 397 first to describe a mechanism of long-term presynaptic structural and functional plasticity that Immunohistochemistry and Microscopy 432 433
Acute rat hippocampal slices were made as described below for electrophysiological recordings 434
and allowed to recover for at least 1 hour after slicing. Slices were incubated in beakers containing 435 ACSF and drug treatments described in Results and underwent constant oxygenation. Slices 436
were fixed immediately after treatments in 4% PFA in PBS overnight at RT. Slices were washed 437 twice in PBS then incubated in blocking buffer (4% BSA in PBS + 0.1% Tx-100) for 1 hour at RT. 438
Primary antibodies (CB1, 1:1000, Immunogenes (Budapest, Hungary); Synapsin-1 1:1000 439
Synaptic Systems (Goettingen, Germany) #106001; Bassoon, 1:1000, Enzo Life Sciences 440
(Farmingdale, NY, USA); Paravalbumin, 1:1000, Sigma Aldrich ) were diluted directly into the 441 blocking buffer and floating slices were incubated overnight at 4C. After 4 washes with PBS, slices 442
were incubated in secondary antibodies (Invitrogen) diluted in blocking buffer overnight at 4C. 443
Slices were washed 5X with PBS, then mounted. Images were acquired on a Zeiss LSM 880 with 444
Airyscan using a Plan-Apochromat 63x/1.4 Oil DIC M27 and 1.8X zoom. Images were Airyscan 445 processed prior to analysis. Pixel width and height was 0.049 µm and voxel depth was 0.187 µm. 446
Imaris 9.2 software was used to reconstruct boutons in 3D using the Surface function. Threshold, 447
laser power, and gain were kept constant for each experiment.. CB1 boutons were screened after 448
3D reconstruction to ensure correct identification. Only boutons that fell between 0.01-2 µm 3 , did 449 not touch the image border, and had a sphericity value above 0.3 were considered. For Bassoon 450
( Figure 1C ), a custom-written macro on FIJI was used to remove all Bassoon signal that didn't 451 colocalize with CB1 labeling, then Imaris was used to quantify the bassoon signal. FIJI was used 452
to analyze synapsin puncta intensity ( Figure 4B) was set to 0.5. For confirmation, we also performed Gene Ontology analysis using two other tools. 513
First, filtered lists (|log2 fold change| > 0.5) were analyzed through the use of IPA (QIAGEN Inc., 514
Hilden, Germany, https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). 515
Then, we performed ontology enrichment using a recently published expert-curated knowledge 516 database for synapses ( assistance with Airyscan confocal microscopy acquisition and analysis. We thank Edward 608
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